MAPT and Alzheimer disease: When defining AD pathology as being both Aβ+ and tau+ (ref. 12), we found that 941 (80%) participants had no AD nor LB pathology (AD–/LB–), 74 (6%) only LB pathology (AD–/LB+), 147 (12%) only AD pathology (AD+/LB–) and 20 (2%) both AD and LB pathology (AD+/LB+).